Erasca Inc (ERAS : NASDAQ)
Common Stock
$13.27
USD
-1.64 (-11.00%)
Last updated: 2026-11-05
Follow ERAS
ERAS
Erasca Inc
WealthAwesomePerformance
1 Day
+1.84%
1 Week
-1.39%
1 Month
+1.29%
YTD
+6.65%
Key Statistics
Market Cap
$5.21B
52W High
$24.28
52W Low
$2.10
P/E Ratio
-
50 Day MA
$15.35
200 Day MA
$15.05
Beta
0.65
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/5/2026 | $14.91 | $15.18 | $13.17 | $13.27 | $13.27 | 6,681,490 |
| 11/4/2026 | $15.09 | $15.13 | $14.18 | $14.91 | $14.91 | 3,494,409 |
| 11/3/2026 | $14.30 | $15.00 | $14.06 | $14.64 | $14.64 | 3,798,381 |
| 11/2/2026 | $14.76 | $15.38 | $13.72 | $14.05 | $14.05 | 4,388,520 |
| 10/30/2026 | $14.66 | $15.01 | $14.04 | $14.35 | $14.35 | 3,749,200 |
| 10/29/2026 | $15.11 | $15.45 | $14.66 | $14.98 | $14.98 | 2,250,279 |
| 10/28/2026 | $14.90 | $15.32 | $14.45 | $15.12 | $15.12 | 3,385,923 |
| 10/27/2026 | $14.95 | $15.26 | $14.72 | $15.22 | $15.22 | 5,085,199 |
| 10/26/2026 | $14.58 | $15.47 | $14.54 | $14.99 | $14.99 | 6,466,114 |
| 10/23/2026 | $13.99 | $14.45 | $13.44 | $14.39 | $14.39 | 3,499,900 |
Analyst Price Targets
Based on 9 analysts covering ERAS · as of Oct 5, 2026
Wall Street analysts forecast ERAS stock price to rise 81.7% over the next 12 months.
Consensus
Buy4.33 / 5.00
Avg. Target
US$24.11
+81.7% Upside
Current Price
US$13.27
Last close
Analyst Breakdown (9 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ERAS's historical volatility
30-Day Vol
68.0%
Annualized
90-Day Vol
63.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$11.10
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$12.50 | US$9.89 – US$15.81 |
| 60 trading days | US$11.78 | US$8.45 – US$16.42 |
| 90 trading days | US$11.10 | US$7.39 – US$16.67 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-147.74M
- Profit Margin
- 0.00%
- ROE (TTM)
- -78.25%
- EPS (Diluted)
- -0.95
- Book Value
- 1.16
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About ERAS.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| INM | InMed Pharmaceuticals Inc | $17.50 | +941.67% |
| OMH | Ohmyhome Limited Ordinary Shares | $15.55 | +432.53% |
| CRIS | Curis Inc | $1.11 | +56.34% |
| PMAX | Powell Max Limited Class A Ordinary Shares | $1.04 | +54.07% |
| RFAIR | RF Acquisition Corp II Right | $0.24 | +50.00% |
| CRCT | Cricut Inc | $8.88 | +48.74% |
| LYEL | Lyell Immunopharma Inc | $15.43 | +43.27% |
| GENVR | Gen Digital Inc. Contingent Value Rights | $4.03 | +42.40% |
ERAS.US news timeline
1 article covering ERAS.US, most recent first
Latest